294 related articles for article (PubMed ID: 19620707)
1. Vinyl sulfones as antiparasitic agents and a structural basis for drug design.
Kerr ID; Lee JH; Farady CJ; Marion R; Rickert M; Sajid M; Pandey KC; Caffrey CR; Legac J; Hansell E; McKerrow JH; Craik CS; Rosenthal PJ; Brinen LS
J Biol Chem; 2009 Sep; 284(38):25697-703. PubMed ID: 19620707
[TBL] [Abstract][Full Text] [Related]
2. Allicin and derivates are cysteine protease inhibitors with antiparasitic activity.
Waag T; Gelhaus C; Rath J; Stich A; Leippe M; Schirmeister T
Bioorg Med Chem Lett; 2010 Sep; 20(18):5541-3. PubMed ID: 20692829
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.
Scheidt KA; Roush WR; McKerrow JH; Selzer PM; Hansell E; Rosenthal PJ
Bioorg Med Chem; 1998 Dec; 6(12):2477-94. PubMed ID: 9925304
[TBL] [Abstract][Full Text] [Related]
4. Crystal Structures of TbCatB and rhodesain, potential chemotherapeutic targets and major cysteine proteases of Trypanosoma brucei.
Kerr ID; Wu P; Marion-Tsukamaki R; Mackey ZB; Brinen LS
PLoS Negl Trop Dis; 2010 Jun; 4(6):e701. PubMed ID: 20544024
[TBL] [Abstract][Full Text] [Related]
5. Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents.
Massai L; Messori L; Micale N; Schirmeister T; Maes L; Fregona D; Cinellu MA; Gabbiani C
Biometals; 2017 Apr; 30(2):313-320. PubMed ID: 28283781
[TBL] [Abstract][Full Text] [Related]
6. The Inhibition of Cysteine Proteases Rhodesain and TbCatB: A Valuable Approach to Treat Human African Trypanosomiasis.
Ettari R; Previti S; Tamborini L; Cullia G; Grasso S; Zappalà M
Mini Rev Med Chem; 2016; 16(17):1374-1391. PubMed ID: 27156518
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors.
Rocha DA; Silva EB; Fortes IS; Lopes MS; Ferreira RS; Andrade SF
Eur J Med Chem; 2018 Sep; 157():1426-1459. PubMed ID: 30282318
[TBL] [Abstract][Full Text] [Related]
8. Update on relevant trypanosome peptidases: Validated targets and future challenges.
Alvarez VE; Iribarren PA; Niemirowicz GT; Cazzulo JJ
Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140577. PubMed ID: 33271348
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Chen YT; Brinen LS; Kerr ID; Hansell E; Doyle PS; McKerrow JH; Roush WR
PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20856868
[TBL] [Abstract][Full Text] [Related]
10. Targeting cysteine proteases in trypanosomatid disease drug discovery.
Ferreira LG; Andricopulo AD
Pharmacol Ther; 2017 Dec; 180():49-61. PubMed ID: 28579388
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones.
Shenai BR; Lee BJ; Alvarez-Hernandez A; Chong PY; Emal CD; Neitz RJ; Roush WR; Rosenthal PJ
Antimicrob Agents Chemother; 2003 Jan; 47(1):154-60. PubMed ID: 12499184
[TBL] [Abstract][Full Text] [Related]
12. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of macrocyclic trypanosomal cysteine protease inhibitors.
Chen YT; Lira R; Hansell E; McKerrow JH; Roush WR
Bioorg Med Chem Lett; 2008 Nov; 18(22):5860-3. PubMed ID: 18585034
[TBL] [Abstract][Full Text] [Related]
14. Identification of a new class of nonpeptidic inhibitors of cruzain.
Brak K; Doyle PS; McKerrow JH; Ellman JA
J Am Chem Soc; 2008 May; 130(20):6404-10. PubMed ID: 18435536
[TBL] [Abstract][Full Text] [Related]
15. Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.
Mott BT; Ferreira RS; Simeonov A; Jadhav A; Ang KK; Leister W; Shen M; Silveira JT; Doyle PS; Arkin MR; McKerrow JH; Inglese J; Austin CP; Thomas CJ; Shoichet BK; Maloney DJ
J Med Chem; 2010 Jan; 53(1):52-60. PubMed ID: 19908842
[TBL] [Abstract][Full Text] [Related]
16. Cruzain inhibitors: efforts made, current leads and a structural outlook of new hits.
Martinez-Mayorga K; Byler KG; Ramirez-Hernandez AI; Terrazas-Alvares DE
Drug Discov Today; 2015 Jul; 20(7):890-8. PubMed ID: 25697479
[TBL] [Abstract][Full Text] [Related]
17. Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors.
Bova F; Ettari R; Micale N; Carnovale C; Schirmeister T; Gelhaus C; Leippe M; Grasso S; Zappalà M
Bioorg Med Chem; 2010 Jul; 18(14):4928-38. PubMed ID: 20598553
[TBL] [Abstract][Full Text] [Related]
18. Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.
Royo S; Schirmeister T; Kaiser M; Jung S; Rodríguez S; Bautista JM; González FV
Bioorg Med Chem; 2018 Sep; 26(16):4624-4634. PubMed ID: 30037754
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
Yang PY; Wang M; Li L; Wu H; He CY; Yao SQ
Chemistry; 2012 May; 18(21):6528-41. PubMed ID: 22488888
[TBL] [Abstract][Full Text] [Related]
20. Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum.
Arastu-Kapur S; Ponder EL; Fonović UP; Yeoh S; Yuan F; Fonović M; Grainger M; Phillips CI; Powers JC; Bogyo M
Nat Chem Biol; 2008 Mar; 4(3):203-13. PubMed ID: 18246061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
